Colorectal cancer is one of the most common cancers affecting men and women in the United States. In 2005, 10% of all new cancer cases in men will be colorectal; for women, 11% of new cases will be colorectal. The disease is the third most frequent cancer occurring in both sexes. Colorectal cancer also is the third most frequent cause of death for men and women, and more than 56,000 cancer deaths in 2005 will be attributed to colorectal cancer. Chemotherapy options for treatment of the disease remained relatively stagnant until the approval of irinotecan in 1996 followed by capecitabine, oxaliplatin, and the new targeted agents. The new agents have improved effi cacy of treatment for colorectal cancer and the lives of patients with advanced disease. With the new options for treatment come increased nursing and patient-teaching responsibilities, as well as increased costs associated with the newer drugs in the armamentarium of chemotherapy agents. Formulary budgets are seeing dramatic rises in expenditures for the new, targeted therapy treatments; discussion of the most appropriate therapies may be considered. This article will discuss epidemiology of colorectal cancer, treatment options in advanced colorectal cancer, and nursing care crucial to patients undergoing chemotherapy. Discussion of economic impact also will be presented.
C
olorectal cancer is common in men and women. More than 56,000 people will die of the disease in the United States in 2005 (Jemal et al., 2005) . Including Europe, the number rises to about 200,000 deaths (Midgley & Kerr, 2000b) . Early diagnosis with better screening has improved overall survival for patients with colorectal cancer. Unfortunately, more than 50% of new patients present with stage III or metastatic disease, and half of all people with colorectal cancer are diagnosed with recurrent or metastatic disease (Xiong & Ajani, 2004) . Therefore, screening and early diagnosis are crucial in helping to reduce mortality.
Because more patients with colorectal cancer present with later-stage disease, effective treatments are needed. Treatments usually include systemic chemotherapy. Patients often receive a combination of surgery, chemotherapy, and possibly radiation therapy in the treatment of stage III or advanced colorectal cancer. Although improvements have been made in surgical and radiation therapy techniques in the treatment of advanced colorectal cancer, 5-fl uorouracil (5-FU) has been the mainstay of chemotherapy for this patient population (Midgley The introduction of irinotecan in 1996, followed by the fi rst new platinum analog agent, oxaliplatin, in 2002, offered considerable advances in chemotherapy for advanced and metastatic colorectal cancer (Schrag, 2004 ). An oral fluorouracil agent, capecitabine, was released in 1998 and has been shown to have activity in colorectal cancer. Two new monoclonal antibody agents, bevacizumab and cetuximab, were approved in 2004 for the treatment of patients with metastatic colorectal cancer. The agents are different in tumor effects and side-effect profi les and may This material is protected by U.S. copyright law. Unauthorized reproduction is prohibited. To purchase quantity reprints, please e-mail reprints@ons.org or to request permission to reproduce multiple copies, please e-mail pubpermissions@ons.org. be added to conventional chemotherapy for treatment of patients with colorectal cancer. The targeted therapies are unique and expensive. Their addition to hospital formularies may be scrutinized because of added costs. Oncology nurses should know the most recent information about colorectal cancer treatments and be able to safely administer the agents. Knowledge of the potential increase in pharmaceutical costs is essential as well; rising healthcare costs increasingly are under study as providers and institutions struggle to provide quality care under constraints (Ginsburg, 2004) .
Chemotherapy Options for Advanced and Metastatic Colorectal Cancer
Surgery still is the primary curative modality for the initial treatment of colorectal cancer. Overall, 60%-70% of patients undergoing resection are cured of the disease; those without regional node involvement have a cure rate of 75%-90% (Helm et al., 2003) . Recurrences often happen during the fi rst few years after surgery. Recurrence in colorectal cancer usually is not local and often shows up in the liver, lungs, and bone.
History of 5-Fluorouracil
5-FU has been the active agent in the treatment of colorectal cancer and has been in use since the 1960s (Midgley & Kerr, 2000b) . The drug is a prodrug, a fl uorinated analog of uracil. 5-FU achieves its cytotoxic effect by conversion to 5-fl uoro-deoxyuridine monophosphate, an inhibitor of thymidylate synthase, which is irreversible (Van Cutsem, Cunningham, Maroun, Cervantes, & Glimelius, 2002) . It inhibits DNA synthesis and leads to cellular death. 5-FU is one of the oldest drugs in the armamentarium of chemotherapy agents, having fi rst been synthesized in the 1950s (Nicum, Midgley, & Kerr, 2003) . Because of the poor oral absorption associated with 5-FU, the drug has been administered most frequently as a bolus injection; however, studies have shown that the drug is a time-dependent agent that causes increased cytotoxicity by prolonging exposure and extending infusion time (Rich et al., 2004) . The actual half-life of 5-FU is 8-14 minutes in the plasma, and it is a cellcycle-specifi c agent (Nicum et al.) .
Modulation of 5-FU has been tried with levamisole and notably folinic acid (leucovorin [LV] ). Levamisole has fallen out of favor and has been shown to have no impact on disease-free survival and overall survival when used alone (Andre & de Gramont, 2004) . Leucovorin modulates 5-FU by slowing the catabolism of the chemotherapy, essentially prolonging the intracellular activity of the drug (Rich et al., 2004) . Researchers have studied numerous 5-FU schedules, including bolus or continuous infusion administration, in an effort to improve effi cacy (Rich et al.) . LV with 5-FU had become the standard for patients with stage III disease requiring adjuvant therapy, but recent trial results with oxaliplatin challenge that standard (Andre & de Gramont) . The drug combination of 5-FU/LV with oxaliplatin or irinotecan plays a prominent role in the treatment of patients with advanced or metastatic colorectal cancer.
Irinotecan
Irinotecan (Camptosar ® , Pfi zer Inc., New York, NY) is a synthetic analog of camptothecan. The signifi cant cytotoxic activity of irinotecan found in patients who previously had received 5-FU indicated that no crossover resistance occurred between 5-FU and irinotecan and prompted approval by the U.S. Food and Drug Administration (FDA) in 1996, initially as second-line chemotherapy for patients who fail or no longer respond to 5-FU-based therapy. Irinotecan now is approved in combination with 5-FU/LV for fi rst-line treatment of advanced colorectal cancer, although it was not recommended in the adjuvant setting in the most recent update of the National Comprehensive Cancer Network (NCCN) guidelines (NCCN, 2005b) . The major side effects associated with irinotecan are diarrhea, early and late onset, and neutropenia (Saltz et al., 2000; Wilkinson, 2001 ).
Capecitabine
Capecitabine (Xeloda ® , Roche Laboratories, Nutley, NJ), a 5-FU prodrug that is metabolized to 5-FU primarily in tumor tissues in the body, is indicated as fi rst-line treatment for metastatic colorectal cancer as a single agent (Hoff et al., 2001) . The company producing the drug also has submitted a fast-track approval application for the adjuvant setting, based on favorable trial results from the X-ACT study, in which capecitabine was shown to be as effective as bolus 5-FU/LV in the adjuvant treatment of colorectal cancer (Scheithauer et al., 2003) . Patients treated with capecitabine experienced significantly lower rates of any grade of stomatitis, nausea, and alopecia. However, capecitabine produced a signifi cantly higher incidence of hand-foot syndrome, also known as palmar plantar erythrodysesthesia.
Oxaliplatin
Oxaliplatin (Eloxatin TM , Sanofi-Synthelabo, Inc., New York, NY) is a thirdgeneration platinum analog. It exhibits strong synergistic cytotoxic activity with 5-FU. The addition of oxaliplatin to 5-FU/LV (FOLFOX regimen) demonstrated an increase in performance status and overall survival in patients with metastatic colorectal cancer. The combination has become the standard fi rst-line therapy in the palliative setting, and oxaliplatin now is approved in the adjuvant setting as well (Grothey & Goetz, 2004) . Side effects associated with oxaliplatin include a dose-limiting neurotoxicity; myelosuppression and gastrointestinal toxicity are less frequent (Berg, 2003) .
Determining Sequence of Chemotherapy for Advanced Colorectal Cancer
Healthcare providers have several choices in the treatment of patients with advanced or metastatic colorectal cancer. Use of treatment guidelines such as those from the NCCN can help to clarify the role of irinotecan, capecitabine, oxaliplatin, and newer therapies. Combinations of 5-FU/LV with irinotecan or oxaliplatin have been demonstrated as effective therapy for metastatic colorectal cancer; however, clinicians have struggled to answer the question of what is the ideal sequence of therapy.
A phase III trial compared the two treatments in reverse order (FOLFIRI [LV infusion followed by irinotecan then 5-FU bolus and 46-hour infusion of 5-FU] followed by FOLFOLX6 [LV infusion followed by oxaliplatin, then 5-FU bolus and infusion over 46 hours] or the reverse sequence). The researchers found that although both sequences achieved prolonged survival and effi cacy, their toxicity profi les were dissimilar. More mucositis, nausea, and vomiting occurred with FOLFIRI, and increased neurosensory toxicity occurred with FOLFOX6 (Tournigand et al., 2004) . Initial choices of future therapy for patients with metastatic colorectal cancer should include rigorous patient assessment. Determining susceptibility for different toxicities and choosing treatment sequences based on patient variability are appropriate.
Patients not wanting to endure prolonged or lengthy infusions may decide to opt for primary oral therapy. Additional studies are designed to evaluate the treatment question further, and data should be accessible as results become available.
Innovative Targeted Therapies
Although many chemotherapy combinations are available for the treatment of metastatic colorectal cancer, toxicities are associated with many of them. Treating cancer with chemotherapy has become the standard of care, but patients suffer side effects and toxicities from the drugs. In contrast, targeted therapies are directed toward specifi c pathways involved in tumor growth, maintenance, and metastasis (Meyerhardt & Mayer, 2005) . The inhibition of vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR) has changed standard chemotherapy treatments for metastatic colorectal cancer.
All cells, including cancer cells, require oxygen and nutrition to be viable (CampSorrell, 2003) . Angiogenesis (the formation of blood vessels) is necessary for tumors to survive and essential in the formation of metastases (Muehlbauer, 2003; Wray, Rilo, & Ahmad, 2004) . A tumor sends out signals to nearby endothelial cells to stimulate new blood vessel growth; if the process is inhibited or disrupted, tumor growth should stop, in theory (Wray et al.) . Many new angiogenic growth factors have been identifi ed in colorectal cancer; the new targeted therapies are designed to interfere with tumor blood supply (Muehlbauer; Wray et al.) .
Cetuximab (Erbitux TM , ImClone Systems Incorporated and Bristol Myers Squibb Company, New York, NY) is a chimeric (a genetically fused product containing mouse and human antibodies) monoclonal antibody that binds to EGFRs that are overexpressed on tumor cells (Ng & Cunningham, 2004) . The binding blocks the ability of epidermal growth factor to initiate receptor activation and signaling to the tumor (Punt, 2004) . The cellular pathways are necessary for cell proliferation, apoptosis, angiogenesis, adhesion, and motility (Baselga, 2002) . Cetuximab is approved as second-line treatment in combination with irinotecan or as a single agent in patients with EGFR-positive, metastatic, irinotecan-refractory colorectal cancer (Punt).
Bevacizumab (Avastin TM , Genentech, Inc., South San Francisco, CA) is a recombinant humanized monoclonal antibody against the VEGF molecule. It is 93% human and 7% murine and is thought to be less likely to cause an immune response.
The antibody prevents VEGF from binding to its natural receptors on the vascular endothelium, which then inhibits VEGFinduced angiogenesis (Fernando & Hurwitz, 2004) . Bevacizumab is approved as fi rst-line therapy in combination with 5-FU-based chemotherapy for the treatment of metastatic colorectal cancer.
Since the introduction of 5-FU more than 40 years ago, gradual improvements have been made in the treatment of metastatic colorectal cancer. Newer chemotherapy agents combined with targeted biologic therapy agents have improved response rates, and the overall survival rate for advanced colorectal cancer may approach 24 months. Clinical questions remain as to the optimal sequence and combination of drugs in the treatment of advanced colorectal cancer.
Nursing Management of Patients Receiving Chemotherapy for Advanced Colorectal Cancer
Many of the new agents indicated for the treatment of colorectal cancer have unique toxicity profi les in addition to the traditional side effects of chemotherapy, such as myelosuppression, nausea, vomiting, and diarrhea. Safe administration of therapy for colorectal cancer requires systematic nursing assessment and prompt intervention to prevent or minimize complications. Nurses also play a critical role in educating patients about the potential side effects of therapy and management of the side effects.
Chemotherapy-Induced Diarrhea
Diarrhea is the most common side effect of chemotherapy for colorectal cancer, particularly 5-FU and irinotecan. As many as 80% of patients treated with a 5-FU-based combination regimen develop diarrhea . Diarrhea is a serious complication that can lead to life-threatening dehydration and electrolyte imbalances. Recently, a multidisciplinary group of experts (11 academic practitioners from varying specialties) developed comprehensive guidelines for the management of chemotherapy-induced diarrhea (Benson et al.) . Recommended management begins with detailed assessment of patients, including the number and composition of stools, duration of diarrhea, and associated symptoms such as moderate to severe cramping, nausea and vomiting, decreased performance status, fever, sepsis, neutropenia, frank bleeding, dizziness, abdominal pain and cramping, weakness, and hydration status. Medication profi le and dietary history also should be evaluated to identify factors that may contribute to diarrhea. National Cancer Institute Common Toxicity Criteria (NCI-CTC) grade 1-2 diarrhea with no other associated symptoms is considered uncomplicated diarrhea, whereas grade 1-2 diarrhea with associated symptoms or grade 3-4 diarrhea is classifi ed as complicated (see Figure 1 ). Uncomplicated diarrhea may be managed conservatively, whereas complicated diarrhea must be managed aggressively, according to the recommendations in Table 1 (Benson et al.) .
Chemotherapy-Induced Nausea and Vomiting
Chemotherapy-induced nausea and vomiting (CINV) may be managed according to published guidelines, such as those provided by the NCCN. The most current version of the guidelines can be accessed online at www.nccn.org. Generally, colorectal cancer combination chemotherapy regimens are moderately emetogenic, and antiemetic premedication should include dexamethasone 12 mg by mouth or via IV and a 5-HT3 antagonist, preferably palonosetron 0.25 mg via IV (NCCN, 2005a) . Palonosetron is the Grade 1: increase of < 4 stools per day over baseline; mild increase in ostomy output compared to baseline Grade 2: increase of 4-6 stools per day over baseline; nocturnal stools; moderate increase in ostomy output compared to baseline; not interfering with activities of daily living (ADL) Grade 3: increase of > 7 stools per day over baseline; incontinence; IV fl uids for dehydration; severe increase in ostomy output compared to baseline; interfering with ADL Grade 4: life-threatening consequences (e.g., hemodynamic collapse) Grade 5: death Uncomplicated Grade 1-2 with no complicating signs or symptoms
Complicated
• Grade 1-2 with moderate to severe cramping, nausea and vomiting, decreased performance status, fever, sepsis, neutropenia, frank bleeding, and/or dehydration • Grade 3-4 • Antibiotics (fl uoroquinolones) • Octreotide 100 mcg subcutaneously twice a day with dose escalation up to 500 mcg subcutaneously twice a day until the patient has been free of diarrhea for 24 hours • Chemotherapy should be discontinued and doses should be reduced with subsequent cycles. Grade 1-2 diarrhea persists 48-72 hours.
Grade 1-2 diarrhea progresses to grade 3-4 diarrhea, or patient develops symptoms associated with complicated diarrhea.
Instruct patient to
• Stop all lactose-containing products, alcohol, and high-osmolar supplements.
• Drink 8-10 glasses of liquids daily (such as broth or rehydrating drinks containing electrolyte supplements).
• Eat frequent, small meals following the BRAT (bananas, rice, applesauce, toast) diet. Treatment should be initiated with • Loperamide 4 mg by mouth followed by 2 mg every four hours, not to exceed 16 mg daily.
• Cytotoxic chemotherapy should be held for grade 2 diarrhea and dose reduction considered for subsequent cycles. If the diarrhea resolves within 24 hours, instruct patient to • Slowly add solid food back into the diet (plain pasta; skinless, white chicken meat; scrambled eggs; and other easily digestible foods).
• Avoid cruciferous vegetables such as Brussels sprouts, cabbage, and broccoli.
• Avoid milk and milk products for a week after a diarrhea episode because a transient loss of lactase activity may occur in the bowel, resulting in temporary lactose intolerance.
• Discontinue loperamide after a 12-hour diarrhea-free interval.
• Increase loperamide to 2 mg by mouth every two hours.
• Start oral antibiotics, preferably with fl uoroquinolones. If the diarrhea resolves within 24 hours, instruct patient to • Slowly add solid food back into the diet, as described above.
• Discontinue loperamide after a 12-hour diarrhea-free interval. • Begin second-line agent.
-Octreotide (100 mcg subcutaneously twice a day with dose escalation up to 500 mcg subcutaneously twice a day) -Tincture of opium
• Admit patient to the hospital and treat according to the guidelines for complicated diarrhea.
GRADE OR OCCURRENCE OF DIARRHEA U NCOMPLICATED C OMPLICATED
Note. Based on information from Benson et al., 2004; National Cancer Institute, 1999. only 5-HT3 antagonist that is FDA approved for the prevention of acute and delayed CINV and has a signifi cantly longer halflife than the other commercially available 5-HT3 antagonists (NCCN, 2005a) . Patients who are at high risk for delayed CINV or who have experienced signifi cant acute or delayed nausea and vomiting with previous chemotherapy cycles may benefi t from the addition of aprepitant as an antiemetic. Aprepitant 125 mg by mouth should be administered one hour before chemotherapy on day 1 with a 5-HT3 antagonist and dexamethasone followed by aprepitant 80 mg by mouth and dexamethasone 8 mg by mouth or via IV on days 2 and 3 (NCCN, 2005a). Recommended agents for the prevention of delayed CINV should continue for two to four days after chemotherapy and depend on which antiemetics were prescribed for the prevention of acute nausea and vomiting prior to chemotherapy. If aprepitant is used, it should be continued with dexamethasone on days 2 and 3. If palonosetron is used, the effect is believed to last for fi ve days because of the long life of the drug (40 hours), and repeat dosing with a 5-HT3 antagonist is not recommended. A recent meta-analysis concluded that the addition of a 5-HT3 receptor antagonist to dexamethasone does not improve the antiemetic effect of dexamethasone for preventing delayed CINV (Huang et al., 2004) . Anticipatory nausea and vomiting may be prevented with lorazepam 0.5-2 mg by mouth the night before and morning of chemotherapy (NCCN, 2005a) .
Oxaliplatin
The most common adverse effects associated with oxaliplatin are neurotoxicity, fatigue, myelosuppression, nausea, vomiting, diarrhea, and allergic reactions . Oxaliplatin infusions are administered over two hours and are compatible only with dextrose 5% and water. Oxaliplatin is considered moderately emetogenic.
Hypersensitivity Reactions
Hypersensitivity reactions may occur in about 10% of patients receiving oxaliplatin, but less than 3% experience severe reactions Dold et al., 2002; Qureshi et al., 2003) . The incidence of hypersensitivity reactions increases with repeated dosing, occurring during or shortly after infusion in patients who have received a median of seven infusions (Gammon, Bhargava, & McCormick, 2004 ). Symptoms range from mild (e.g., transient rash, fever, rigors, urticaria, facial flushing) to severe (e.g., dyspnea, bronchospasm, hypotension, anaphylaxis). If any symptoms of hypersensitivity reaction occur, infusion should be stopped immediately. Mild hypersensitivity reactions may be treated with an antihistamine and corticosteroid; after symptoms resolve, the infusion can be restarted with an extended infusion time of six hours. Moderate or severe hypersensitivity reactions should be managed with epinephrine, corticosteroids, diphenhydramine, bronchodilators, and/or oxygen according to institutional protocols. Patients who experience moderate hypersensitivity reactions can be rechallenged with oxaliplatin on a different day with an extended infusion time of six hours and aggressive premedication including dexamethasone, cimetidine, diphenhydramine, acetaminophen, and a 5-HT3 antagonist (Dold et al.) . Some clinicians suggest that patients who experience severe hypersensitivity reactions no longer should be treated with oxaliplatin; others have reported successful retreatment using a desensitization protocol (Gammon et al.) .
Neurotoxicity
Two distinct neurotoxic syndromes are associated with oxaliplatin: an acute, reversible, peripheral sensory neuropathy and a chronic, cumulative sensory neuropathy. Although neuropathy occurred in 92% of patients treated with the FOLFOX4 regimen (oxaliplatin 85 mg/m 2 via IV over two hours, day 1, with LV 200 mg/m 2 via IV over two hours, days 1 and 2, with 5-FU 400 mg/m 2 via IV bolus, then 600 mg/m 2 via IV over 22 hours, days 1 and 2, repeated every two weeks [Wilkes, 2005] ), most of the episodes were grade 1 or 2 and almost all of the patients reported resolution of their symptoms by one year after treatment .
Acute neuropathy occurs in 65% of patients (Kemeny et al., 2004) and may begin during infusion but is self-limiting and resolves within 14 days after treatment. Symptoms include paresthesia, dysesthesia, or hypoesthesia (numbness, tingling, or a "pins and needles" sensation) in the hands, feet, perioral area, or throat. Patients also may report jaw spasms, an unusual sensation in the tongue, eye pain, chest pressure, or muscle cramping described as involuntary clenching of the hands, feet, or calves or as the inability to release their grip (Cersosimo, 2005) . Acute neuropathy is unusual in that it might be precipitated by exposure to cold temperatures, objects, or liquids. Another manifestation of acute neuropathy is pharyngolaryngeal dysesthesia, a loss of sensation of breathing which presents as an uncomfortable sensation of throat tightness, jaw pain, dysphagia, or dyspnea (SanofiSynthelabo Inc., 2004). The sensation usually occurs after ingestion of a cold beverage or ice chips or after inhalation of cold air. Patients describe the sensation as similar to the "brain freeze" experienced after drinking a cold milkshake rapidly, except that the uncomfortable feeling occurs in the throat. Although transient, it can be quite frightening because patients might feel as if they are unable to breathe or catch their breath.
Chronic peripheral neuropathy is dose limiting and cumulative, occurring in 57% of patients (Kemeny et al., 2004 ) after 6-10 cycles with a cumulative dose > 540 mg/m 2 (Cersosimo, 2005) , but it usually resolves within 6-12 months after completion of therapy . The peripheral neuropathy is primarily sensory but can progress to sensorimotor. It begins with paresthesia in a stocking-glove distribution, affecting the distal fi ngertips and toes fi rst and progressing proximally (Wilkes, 2002) . In some cases, vibration, propioception, and temperature sensation may be affected, and the changes can affect activities of daily living that require fi ne motor coordination, such as buttoning shirts, writing, and typing. Patients should be comprehensively assessed for the presence of peripheral neuropathies.
In a retrospective analysis, the administration of calcium gluconate 1 g and magnesium sulfate 1 g over 15 minutes before and after oxaliplatin administration signifi cantly reduced the incidence and severity of acute and chronic neuropathy (Gamelin et al., 2004) . Severe acute neuropathy impairing activities of daily living (NCI-CTC grade 3) occurred in 7% of patients treated with calcium and magnesium infusions compared to 26% of the untreated control group (p = 0.001), and grade 3 chronic neuropathy occurred in 20% of the control group compared to 8% of the treatment group (p = 0.003). A prospective, placebo-controlled, randomized trial is under way to confi rm the results. Another strategy that may reduce the incidence of acute neuropathy is to extend infusion time of oxaliplatin to six hours (Giacchetti et al., 2000; Kemeny et al., 2004; Rothenberg et al., 2003) . Preliminary studies of pharmacologic agents, including gabapentin 300 mg by mouth three times a day, carbamazepine 400 mg per day, or celecoxib 200 mg by mouth twice a day, have suggested a decreased incidence and/or severity of peripheral neuropathy (Agafi tei et al., 2004; Foladore et al 2003; Hoffman, 2004) . Based on a review of the available studies evaluating pharmacologic preventive measures, Cersosimo (2005) proposed that calcium and magnesium infusions be considered the fi rst-line option and gabapentin the second-line option for the prevention and treatment of acute oxaliplatin neuropathy. Although limited data exist, the two strategies have demonstrated the most benefi t with the least toxicity.
Capecitabine
The most common adverse effects of capecitabine are hand-foot syndrome, fatigue, myelosuppression, nausea, vomiting, diarrhea, mucositis, and hyperbilirubinemia (Hoff et al., 2001 ). Patients should be educated to take capecitabine orally twice a day approximately 12 hours apart within 30 minutes of a meal (Hoff et al.) . Capecitabine commonly is prescribed for 14 days followed by a one-week rest period.
Hand-Foot Syndrome
Hand-foot syndrome (also known as palmar-plantar erythrodysesthesia) affects more than 50% of patients (see Figure 2) and is characterized by numbness, dysesthesia, paresthesia, tingling, swelling, or erythema (Lassere & Hoff, 2004 ). Typically, patients experience dysesthesia perceived as a tingling sensation of the palms and soles that progresses within three to four days to a burning pain with swelling and erythema (Lassere & Hoff) . It can progress to moist desquamation, blistering, ulceration, or severe pain, which affects the ability to perform activities of daily living (Scheithauer & Blum, 2004) . Topical emollients such as lanolin-containing preparations (Bag Balm ® , Dairy Association Co., Inc., Lyndonville, VT) (Scheithauer & Blum) or urea-containing preparations such as Eucerin ® (Beiersdorf, A.G., Wilton, CT) (Pendharkar & Goyal, 2004) are helpful for prevention and treatment. Preliminary evidence suggests that celecoxib 400 mg by mouth twice a day during treatment may reduce the incidence of hand-foot syndrome, myelosuppression, and mucositis, although the drug is under scrutiny by the FDA for possible cardiovascular effects (El-Rayes et al., 2004) . In a retrospective, case-control analysis of 67 patients to evaluate the effect of celecoxib on the incidence of hand-foot syndrome in patients treated with capecitabine, Lin, Morris, and Ayers (2002) determined that patients who were taking celecoxib concomitantly with capecitabine had a signifi cantly reduced incidence of > grade 1 hand-foot syndrome (12.5% versus 34.3%, p = 0.037) and a nonsignifi cant decrease in > grade 2 hand-foot syndrome (3.1% versus 17.1%, p = 0.11). They observed that the incidence of > grade 2 diarrhea also was signifi cantly lower in the capecitabine and celecoxib group (3.1% versus 28.6%, p = 0.005).
Pyridoxine (vitamin B6) also has been studied at various doses, but randomized, controlled trials are necessary, and its impact on the effi cacy of capecitabine is unknown (Lassere & Hoff, 2004; Scheithauer & Blum, 2004) . Other agents that warrant further study for the prevention of hand-foot syndrome include nicotine patches, topical dimethyl sulfoxide, and Biafi ne ® (Johnson and Johnson, New Brunswick, NJ), a water-based topical emollient (Scheithauer & Blum) .
Because capecitabine is an oral agent that patients self-administer at home, nurses are not present to assess for potential side effects. However, nurses play an important role in patient education regarding potential side effects, symptom management, and when to report symptoms. Despite multiple comfort measures to minimize the discomfort of hand-foot syndrome, the only effective strategy is to interrupt treatment and reduce the dose of capecitabine (see Table  2 and Figure 3 ).
Irinotecan
Dose-limiting toxicities of irinotecan include delayed-onset diarrhea and neutropenia. Other side effects include acute diarrhea with cholinergic syndrome, nausea, vomiting, anorexia, and mucositis (Cunningham et al., 1998) . Oncology nurses must be aware of the impact that severe diarrhea may have for patients with colorectal cancer and intervene accordingly.
Diarrhea
Diarrhea occurs in 50%-80% of patients treated with irinotecan and may be acute or delayed (Barbounis, Koumakis, Vassilomanolakis, Demiri, & Efremidis, 2001) . Acute diarrhea occurs within 24 hours of administration and is part of a cholinergic syndrome that also may include rhinitis, hypersalivation, miosis, lacrimation, diaphoresis, fl ushing, and abdominal cramping. Cholinergic symptoms should be treated with atropine 0.25-1 mg via IV or subcutaneously. Delayed-onset diarrhea can be very severe, leading to life-threatening dehydration and electrolyte imbalances. It occurs a median of fi ve days after every three-week administration and 11 days following weekly administration of irinotecan (Alimonti et al., 2004) . The median duration is fi ve to seven days. Patients should be educated to start loperamide 2 mg at the fi rst episode of diarrhea and to continue loperamide 2 mg by mouth every two hours until diarrhea has resolved for 12 hours. The recommended maximum dose of loperamide is 16 mg per day, but high-dose loperamide (defi ned as a median of 21 tablets of 2 mg each per day in a trial) has been shown to be safe and effective in patients treated with irinotecan (Abigerges et al., 1994) . Another agent that is effective in controlling irinotecan-induced diarrhea refractory to loperamide is octreotide 500 mcg subcutaneously three times a day (Barbounis et al., 2001) . A prospective study comparing octreotide 100 mcg versus 500 mcg subcutaneously showed that the 500 mcg dosing was signifi cantly more effective in controlling chemotherapy-induced diarrhea (90% versus 61%, p < 0.05) (Goumas et al., 1998) . Octreotide should be discontinued within 24 hours after the resolution of diarrhea to minimize the risk of ileus development.
FIGURE 2. PATIENT WITH GRADE II HAND-FOOT SYNDROME SECONDARY TO ORAL CAPECITABINE

Bevacizumab
The most common side effects of bevacizumab in phase I and II clinical trials were hypertension, proteinuria, thrombosis, and bleeding (Kabbinavar et al., 2003) . In a phase III, randomized, controlled trial comparing irinotecan, bolus 5-FU, and LV (IFL) and IFL plus bevacizumab, only hypertension and gastrointestinal perforation were signifi cantly more common in patients treated with bevacizumab . Additionally, the FDA sent a postmarketing warning letter updating clinicians about the increased incidence of serious arterial thromboembolic events associated with the use of bevacizumab (FDA, 2005) , and the Avastin package insert subsequently was revised (Genentech, Inc., 2005) .
Bevacizumab is an extremely well-tolerated monoclonal antibody. Infusion reactions are rare (3%), and standard premedications are not necessary. The infusion-time recommendations state that the fi rst dose should be administered over 90 minutes to detect potential hypersensitivity reactions. If tolerated, the second infusion may be administered over 60 minutes, and the third and all subsequent infusions may be administered over 30 minutes (Genentech, Inc., 2005; Kabbinavar et al., 2003) . If a hypersensitivity reaction occurs, premedication with diphenhydramine 50 mg via IV and a prolonged infusion time minimize the risk of subsequent infusion reactions (Kabbinavar et al.) .
Hypertension
Hypertension occurs in 33% of patients and may be managed with standard antihypertensive medications, such as diuretics, angiotensin-converting-enzyme inhibitors, calcium-channel blockers, or beta-blockers . Researchers are attempting to further defi ne the relationship of hypertension as a possible and unusual response to angiogenic growth factors (Sane, Anton, & Brosnihan, 2004) . Blood pressure should be monitored routinely prior to the administration of bevacizumab and at least every two to three weeks during treatment.
Proteinuria
Proteinuria was reported as a potential side effect of bevacizumab in phase I and II trials, but the incidence of proteinuria was similar between IFL-treated patients who received bevacizumab and those who did not . Proteinuria generally is clinically insignifi cant and reversible after completion of therapy. Nurses can monitor for proteinuria by checking a urine dipstick for protein prior to the administration of bevacizumab and at regular intervals throughout treatment. If a patient develops NCI grade 2 proteinuria (defi ned as 2+ or higher dipstick reading), a healthcare provider should obtain a 24-hour urine collection for further evaluation. In most Genentech-sponsored clinical trials, bevacizumab was not administered if the 24-hour urine collection showed > 2 g of protein in 24 hours, and the drug was resumed when proteinuria fell below 2 g in 24 hours (Genentech, Inc., 2005) .
Bleeding and Thrombosis
Mild epistaxis is the most common bleeding complication, occurring in approximately 50% of patients (Kabbinavar et al., 2003) . It generally resolves within fi ve minutes without medical intervention or dose adjustment, and patients should be instructed to apply pressure until bleeding resolves. Gastrointestinal hemorrhage or other serious hemorrhagic complications rarely occur Kabbinavar et al.) . Thrombotic events occurred more frequently in bevacizumab-treated patients in the phase II trial (19% versus 9%, p value not reported), but the increased incidence was not statistically signifi cant in the phase III trial (19.4% versus 16.2%, p = not signifi cant) (Hurwtiz et al.; Kabbinavar et al.) . Postmarketing analysis of 1,745 patients in fi ve clinical trials revealed an increased incidence of arterial thromboembolic events (4.4% versus 1.9%), cerebrovascular arterial events (1.9% versus 0.5%), and cardiovascular arterial events (2.1% versus 1.0%) (Genentech, Inc., 2005) . Patients who had clinically signifi cant cardiovascular disease, ascites, regular use of aspirin or nonsteroidal antiinfl ammatory agents, preexisting bleeding disorders, coagulopathies, need for anticoagulation, or central nervous system metastases were excluded from the clinical trials of bevacizumab (Hurwitz et al.; Kabbinavar et al.) . Patients should be assessed for and educated about signs of bleeding or thrombosis (e.g., swelling, pain in leg or calf, abdominal pain, chest pain, dyspnea, syncope, weakness, new onset of severe headache, tachycardia, arrhythmias).
Gastrointestinal Perforation and Delayed Wound Healing
The antiangiogenesis effect of bevacizumab may delay wound healing by inhibiting dermal wound angiogenesis, so bevacizumab should not be administered within 28 days after surgery or when serious wounds are present. Gastrointestinal perforation occurred in 1.5% of patients treated with bevacizumab in the phase III trial and had variable presentation . Nurses should assess for the presence of wounds and ensure that all previous surgical incisions are well healed prior to the administration of bevacizumab. Any patient complaint of abdominal pain, especially with vomiting or constipation, should be evaluated promptly.
Cetuximab
Common side effects associated with cetuximab are skin reactions and hypersensitivity reactions . The fi rst infusion should be administered over
• Use topical emollients to keep skin moisturized.
• Reduce friction, pressure, and heat exposure to the hands and feet.
• Take short showers with tepid water and avoid hot tubs.
• Avoid tight gloves, socks, and shoes.
• Avoid pressure on palms and soles (e.g., chopping vegetables, hand-washing dishes, excessive exercise) • Immerse hands and feet in cool water to relieve discomfort.
• Use topical emollients.
FIGURE 3. PATIENT EDUCATION FOR THE MANAGEMENT OF HAND-FOOT SYNDROME ASSOCIATED WITH CAPECITABINE
Note. Based on information from National Cancer Institute, 1999; Roche Laboratories, Inc., 2003. 120 minutes, and subsequent infusions may be administered over 60 minutes if patients tolerate the fi rst infusion without hypersensitivity reactions. An inline fi lter (low protein binding, 0.22 mcM) and nonpolyvinyl chloride bag and tubing should be used for administration. Premedication with diphenhydramine 50 mg via IV is recommended to prevent hypersensitivity reactions, but no routine antiemetic premedications are needed (ImClone Systems Incorporated and Bristol-Myers Squibb Company, 2004) . If a hypersensitivity reaction occurs, the infusion should be stopped immediately and treatment should be initiated per institutional protocol with epinephrine, corticosteroids, diphenhydramine, bronchodilators, and/or oxygen. Hypersensitivity reactions occur in 20% of patients but rarely are severe (3%), and 90% occur with the fi rst dose (ImClone Systems Incorporated and Bristol-Myers Squibb Company).
Cutaneous Toxicity
An acne-like rash occurs in 85% of patients treated with cetuximab, which is characteristic of any agent that inhibits the EGFR pathway Saltz et al., 2004) . EGFR plays an important role in maintaining the integrity of the skin, and skin reactions associated with cetuximab are thought to be infl ammatory rather than infectious in nature (Yamamoto, Viale, & Zhao, 2004) . The presence and severity of a skin rash are associated with a greater likelihood of response and survival Saltz et al., 2004) .
Patients usually develop a skin rash within three weeks after the start of treatment Saltz et al., 2004) . The rash appears acneiform, follicular, or maculopapular and usually affects the face, chest, and back but generally is not dose limiting (see Figure 4) . Less than 10% of patients require dose adjustment for NCI grade 3 or 4 toxicity, defi ned as a severe rash covering 50% of the body area that may be associated with desquamation or ulceration (see Table  3 ) . The acne-like rash may improve spontaneously within one to two months without a change in treatment and resolves completely without scarring after treatment is completed (Saltz et al., 2004) . Topical antibiotics, topical drying agents, and topical corticosteroids do not appear to affect the course of the rash (Saltz et al., 2004) . However, patients should be educated that topical corticosteroids are not recommended because they may increase the potential for infection. Patients also should be encouraged to avoid sun exposure. If a severe rash occurs, dose delays and/or modifications are recommended. Another cutaneous toxicity is a nail disorder characterized by paronychial infl ammation; cracking and swelling of the lateral nail folds of the fi ngers and toes also was seen in 12% of cetuximab-treated patients (Saltz et al., 2004) . Unlike the skin rash, the cutaneous toxicity tended to persist throughout treatment and in some patients required several months after therapy to heal completely. Soaking the hands in warm water may relieve discomfort and prevent superinfection (Yamamoto et al., 2004) .
Economic Considerations
Generic drug alternatives usually are available once a patent life expires, which means the drug is inexpensive to obtain. Because 5-FU has been available since the 1950s, the drug is extremely economical to use; in some cases, it may cost pennies to purchase. Administration of the drug requires nursing time, IV access, and tubings, which add to the overall cost, but the actual drug purchase price is very low. The average wholesale price of 5-FU in a 5 g powder vial ranges from $24.10-$56.00 (Fleming, 2005) . The average wholesale prices for newer agents are astoundingly high and will have a fi scal impact on pharmacy budgets (see Table 4 ).
The new cancer therapies for advanced colorectal cancer have almost doubled the life expectancy for patients. In a disease that has had very few changes in disease reduction and overall survival, new drugs added to the armamentarium of chemotherapy agents effective in the treatment of advanced colorectal cancer is exciting.
Potent reasons to administer systemic therapy to patients with metastatic colorectal cancer exist. Prior to systemic chemotherapy with 5-FU, the median survival for patients with metastatic colorectal cancer was eight months; with therapy, the number increased to 12 months (Schrag, 2004) . With the addition of irinotecan and oxaliplatin, the median survival rose to 21 months, and new agents bevacizumab and cetuximab may further increase the number (Schrag) . The accompanying rise in drug expenditure for the newer agents coupled with the sheer numbers of patients with colorectal cancer who would be eligible for treatment with the medications is impressive. In addition to the drug purchase costs, method of delivery (longer infusions which may require hospitalization versus shorter infusion times) may affect therapy costs. Few studies have been published that specifi cally examine cost-effectiveness of chemotherapy for colorectal cancer; one published article reported that oxaliplatin was acceptable for stage III cancer only if it could reduce mortality by 20% (Koperna & Semmler, 2003) .
A British study reported on three chemotherapy treatments, including an economic substudy, for 905 patients with advanced colorectal cancer: de Gramont (LV 200 mg/m 2 via IV over two hours on days 1 and 2, with 5-FU 400 mg/m 2 via IV bolus, then 600 mg/m 2 via IV over 22 hours, days 1 and 2, repeated every two weeks) bolus and infusion 5-FU with folinic acid, protracted venous infusion 5-FU, and raltitrexed (via IV every 21 days) (Hale, Cohen, Maughan, & Stephens, 2002) . Many different factors were assessed with regard to cost in the study, including societal costs, side effects, and drug costs. Whether or not a treatment could be administered in the outpatient setting versus the hospital made a difference in overall costs as well. The researchers concluded that although all three regimens were fairly equivalent in overall survival and response, toxicity differed, with patients receiving protracted infusion having more hand-foot symptoms. The raltitrexed group also had more side effects. With regard to drug and treatment costs, the patients in the de Gramont group had signifi cantly higher costs compared to the other treatments for chemotherapy delivery and societal costs; the fi nding was attributed partially to the number of patients in the group who were treated in the hospital. The raltitrexed group was lower in costs of pharmacy and nursing time, but the fi nding was not signifi cant enough to offset the cost of drug acquisition. The group receiving protracted infusion therapy was less expensive to treat overall (Hale et al.) .
A study measuring the cost-effectiveness of second-line treatment with irinotecan versus infusional 5-FU alone was reported by a French research group (Levy-Piedbois et al., 2000) . The researchers looked at 129 patients receiving 5-FU and 127 patients receiving irinotecan who were treated in an outpatient setting. Although the acquisition costs of irinotecan were much higher than for 5-FU, the researchers concluded that even though the least expensive management for metastatic colorectal cancer was 5-FU, the additional cost of irinotecan was balanced by the added months of survival, with a costeffectiveness ratio similar to other cancer treatments (Levy-Piedbois et al.) .
Another study looked at the clinical and economic benefi ts of irinotecan in combination with 5-FU and folinic acid as the fi rstline treatment for metastatic colorectal cancer (Cunningham, Falk, & Jackson, 2002) . Each group had two possible chemotherapy-delivery regimens, although the drugs remained 5-FU with LV in treatment arm B, and irinotecan with 5-FU and LV in arm A. The researchers found that in the setting of fi rst-line therapy, the overall costs for each treatment arm represented the total costs that would be associated with fi rst-line therapy and the costs that would be incurred with disease progression, including the possibility of further drug-acquisition costs . They concluded that the cost effectiveness, along with the clinical evidence of improvement in survival benefi ts, supported the use of irinotecan with 5-FU and LV as fi rst-line therapy for metastatic colorectal cancer .
More research is needed to fully explore the costs associated with chemotherapy treatments for stage III and metastatic colorectal cancer; benefi t versus cost is an issue that is becoming more prominent as newer treatments are approved. However, drug costs are not the only aspect to consider; survival benefi ts versus progression of disease and need for further treatment with chemotherapy agents also factor in to the total economic picture. Cunningham et al. (2004) reported that combining irinotecan and cetuximab for second-and third-line treatment of metastatic colorectal cancer lengthens the median survival time by 1.7 months and that the regimen would cost a little more than $30,000 for an eight-week course of treatment. Adding bevacizumab to 5-FU and LV or irinotecan for eight weeks of therapy totals about $21,000 (Schrag, 2004) . The statistics are dramatic and have created concern about increasing chemotherapy costs. The drugs are considerably more expensive than irinotecan, and drug expenditures for the therapies will impact pharmacy budgets signifi cantly. Research examining the costeffectiveness of the treatments has not been published.
Pharmaceutical Assistance Programs
For patients who meet the income criteria of pharmaceutical companies, assistance programs are available for many of the drugs commonly used in the treatment of patients with metastatic colorectal cancer, including the new biologic agents. Many medication-assistance Web sites may be helpful as resources for enrolling patients in programs designed to help with access to needed drugs (Viale & Mister, 2001 ). The programs usually require information about a patient's medical insurance status, income level, and assets, and most require that patients do not have third-party prescription coverage (Chisholm & DiPiro, 2002; Viale & Mister) .
Conclusion
Patients with metastatic colorectal cancer have more chemotherapy options than ever before. The numbers of patients who eventually will receive systemic chemotherapy are quite high. The addition of irinotecan to standard 5-FU-based chemotherapy with folinic acid increased the drug expenditure and life expectancy for the treatment of this patient population; with new targeted therapies, the economics of chemotherapy treatments for metatastatic colorectal cancer are altered considerably. However, the therapies also confer a survival benefi t; patients with metastatic disease have an expected median survival close to two years (Hoff & Pazdur, 2004) . Further examination of the cost-effectiveness of the new chemotherapy agents needs to be conducted.
Side-effect management of the chemotherapy agents used in the treatment of metastatic colorectal cancer is crucial for oncology nurses; many of the medications cause specifi c side effects that can be managed with appropriate teaching and reinforcement during chemotherapy administration and teaching sessions. Oncology nurses need to be aware of the differences in the administration of the new targeted therapies and the care to be taken with monoclonal antibody agents. Prompt assessment of skin rashes associated with cetuximab and awareness of the potential problems with bleeding and wound healing with bevacizumab are essential to the safe delivery of the agents. With appropriate screening and improved early detection, colorectal cancers may be diagnosed earlier, and for patients with later-stage disease, treatment options have broadened. Oncology nurses should be cognizant of available approved treatments for the disease and administration techniques. Knowledge of the fi scal impact of treatment is important as well.
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